People
Figures converted from JPY at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Governance: B — A Founder-Controlled Wafer Reclaimer With Clean Plumbing
A 55-year-old founder (born Oct 1970) holds 43.89% of the shares and runs both the Japanese parent and every Chinese subsidiary; that is the dominant fact. The board, the audit committee, and the related-party plumbing are unusually clean for a Japanese small-cap of this shape — but minority shareholders are along for whatever ride CEO Nagayoshi Ho decides to take, and the next governance test will be how the listed Shanghai subsidiary (GRITEK) is dealt with as he raises his stake there using parent capital.
The People Running This Company
CEO Ownership (direct + HK Ltd)
CEO Tenure (years)
CEO Stake ($ million, at ¥6,680)
CEO Shares (incl. R.S.TECH HK Ltd)
Nagayoshi Ho (方永義) — Founded predecessor trading company Eikei Shoji (永輝商事) in 1999, set up RS Technologies in December 2010, and today sits as Chairman/Representative Director of every Chinese operating entity in the group: SDGRITEK (Shandong), Beijing GRINM RS, GRITEK (Shanghai STAR-listed), and the Taiwan venture Eyrus Semi. He took the company from a one-product Sanbongi reclaim plant in 2010 to $489M revenue / $59M net income in FY2025. Founder/operator track record is real; concentration of authority is total.
Satoru Endo — Manufacturing director who joined from Rasa Industries in 2011. He is the operating spine of the reclaim plants (Sanbongi, Tainan) and from February 2026 also runs DG Technologies as President. Wafer reclaim is a yield-and-process business, and Endo is the man who runs the floor.
Issei Osawa — Followed CEO Ho from Eikei Shoji in 2012, made director in February 2025, and now runs the Other-segment portfolio: LE System (vanadium-redox-flow batteries), Union Electronics, and the two Aisi Energy entities in Shandong and Panzhihua. He is the CEO's operating proxy in the diversification businesses.
Kiyohide Tomatsu — Joined from regional Kiraboshi Bank in 2023, became director in March 2024 as Strategy & Admin GM. He is the closest thing to a CFO function on the board and the only inside director with meaningful banking-side credibility for refinancings.
The succession question is unanswered. There is no designated successor for Ho, no chairman role separated from CEO, and no formal nominating-committee chair other than Ho himself acting through the Nomination & Compensation Committee. For a company where the founder's networks (especially in China) drive new business, this is the single biggest people-risk.
What They Get Paid
CEO Total Comp FY25 ($M)
Revenue per $1 of CEO Pay
CEO Pay as % of Net Income
| Limit (set at AGM) | Cap | Recipients | FY25 usage |
|---|---|---|---|
| Non-Audit director cash | $3.5M / yr | Up to 6 | $1.95M (55%) |
| Audit Committee director cash | $0.32M / yr | Up to 4 | $0.23M (72%) of outside total |
| Restricted stock (RSU) | $0.64M & 31,000 shares / yr | Non-Audit | Within cap; $0.27M expense |
Pay is not the story here, ownership is. CEO Ho's $1.36M total package is roughly 0.02% of the $59M he and the team produced in net income — and 60% of it is fixed salary, not pay-for-performance. By Japanese mid-cap norms this is unremarkable; by global standards it is laughably restrained for a founder with this much shareholder value created. The 2023 introduction of a tightly-capped restricted-stock plan ($0.64M / 31,000-share annual cap, less than 0.12% of float) is a low-dilution, shareholder-friendly design. Outside directors receive ~$60k each — symbolic, not enough to dim independence, not enough to attract a marquee name either.
Are They Aligned?
Founder Stake
Foreign Investors
Treasury Shares
Skin-in-the-Game (1-10)
Skin in the game: 8/10. CEO Ho's $490M (at ¥6,680/share, May 2026) stake is roughly 360× his annual cash pay. Other directors hold tokens, except Endo (137k shrs) and Osawa (125k shrs) who have meaningful but not life-changing positions. Foreign investors own 62.10% of the float, which gives the stock real liquidity but also means every governance signal — restricted stock grants, the Rasa cross-holding, China subsidiary capital injections — gets scrutinised by people who do not share the Japanese deference reflex.
Insider trading pattern. Japan does not publish Form-4-style individual trades, but the disclosed related-party history shows: CEO Ho's direct stake rose from 7.86% (FY2024) to 8.04% (FY2025) through stock-option exercises totaling $0.43M of strike consideration — i.e., the founder is converting options into shares, not selling. R.S.TECH Hong Kong Ltd has held its 35.85% block unchanged. No large-holder sales reported. The signal is "buying / accumulating," not selling.
Dilution is small and shrinking. The diluted-vs-basic EPS gap has compressed from 2.2% in FY2021 to under 0.4% in FY2025 as legacy 2019 stock-option tranches get exercised and the new RSU program comes in tight. The April 2026 RSU plan announcement (referenced in the yuho) is within the existing $0.64M / 31,000-share cap. Buybacks have not happened — the CFO said in the Feb 2026 briefing that buybacks would be "considered" subject to share-price, cash, and investment progress.
Related-party transactions are real but trivially small.
Total operating-level RPT exposure is $0.63M against $489M in group revenue — 0.13%, immaterial, and the disclosures explicitly state "市場実勢等を勘案して、一般的な取引条件で行っております" (terms based on market practice). The only judgment call is the $15.86M ($6.36M → $15.86M after a FY2025 +$0.45M top-up) strategic stake in Rasa Industries — Endo's former employer — held under the policy-investment rationale. This is not a serious red flag at this size, but it is the kind of position that a clean board should be ready to defend or sell.
Capital allocation. Investment is steered through the China complex: the 2025 capital increase at GRITEK (Shanghai-listed subsidiary) raised RS Tec's ownership in SGRS (Shandong) to ~39% via Gritek, and brought forward the restart of Sanbongi Plant No. 7. Dividend per share rose $0.22 → $0.29 (FY25) → $0.35 guided (FY26); payout is in the 13-14% range, leaving plenty of cash for the $255M reclaim capex plan. No buyback yet. Capital allocation is unambiguously growth-first.
Board Quality
Board Expertise / Independence Scorecard (1–10) — qualitative ranking based on FY2026 disclosure.
Green flags. 4 of 8 directors are TSE-classified independent. Audit Committee is 100% outside (CPA + two lawyers — one Japan, one China). Board attendance was 100% across 16 meetings. Auditor PwC Japan in year four, no non-audit work at parent level, parent audit fee $0.39M is appropriate for the group's size. No internal control weakness disclosed in FY2025.
Yellow flags. (1) Female board representation drops from 25% (FY2025) to 12.5% (FY2026) as lawyer Natsuko Shimizu steps off — a step backwards on diversity, against the prevailing direction of Japanese governance reform. (2) The replacement outside director Nakano joins at age 70 with limited semiconductor exposure; he is a UACJ aluminum/steel veteran chosen for "strategy" credibility rather than industry challenge. (3) No formally separate Nominating & Compensation Committee chair — the CEO makes individual pay proposals and the committee advises. (4) Multiple non-listed Chinese subsidiaries with CEO Ho as Chairman creates a governance black box at the operating-entity level.
The structural concern. CEO Ho controls 43.89% of voting rights through his Hong Kong holding vehicle plus a direct stake. With another 7.94% in a passive Master Trust and 2.58% in a stable individual-name holder (Nasu Material), the practical free float for any contested vote is well under 50%. A determined activist could not displace this management without Ho's consent. The audit committee independence and clean RPT trail are the safeguards minorities actually rely on.
The Verdict
Governance Grade: B.
Skin in the Game (1-10)
Board Independence
Grade: B. A founder-controlled Japanese small-cap with abnormally clean plumbing for its profile.
The strongest positives. Real founder ownership (43.89%) with multi-year option-exercise pattern that screams "accumulating," not selling. A 100%-outside audit committee staffed by a CPA and two lawyers — including a China-qualified lawyer at Nishimura & Asahi, which directly addresses the group's biggest operating risk. 100% attendance across all 16 board meetings and all 13 audit-committee meetings. Modest dilution overhang (under 0.4%) and a tight RSU cap. Related-party transactions exist but total under 0.15% of revenue. Pay is restrained and fixed-heavy — there is no LBO-style enrichment going on here. Big Four auditor (PwC) on a normal multi-year rotation with no off-balance non-audit consulting at the parent.
The real concerns. Concentration of authority: Ho is CEO and Chairman of every Chinese subsidiary that matters, including the Shanghai STAR-Market-listed GRITEK. There is no published successor plan. The board's strategy challenge is light — Nakano is a credible operator but adds aluminum-industry perspective, not deep semiconductor or capital-markets pushback. Cross-shareholding in Rasa Industries ($15.86M, increased in FY2025) is small but exactly the kind of position that needs to be defended explicitly each year. Female representation dropping back below 15% in FY2026 is going in the wrong direction. And the Hong Kong holding company structure for the founder's stake — while routine for cross-border Chinese-Japanese entrepreneurs — carries opacity that purely-domestic governance would not have.
Upgrade catalyst. A formal succession announcement (most likely Endo for operations + Tomatsu or a new hire for capital allocation) plus a buyback would push this to a B+. A separation of Chair and CEO roles, or a named lead independent director with override authority, would push it toward A-.
Downgrade catalyst. Any of three things: (1) a non-arm's-length transaction with the Hong Kong vehicle or with one of Ho's other Chinese ventures, (2) a take-private of the Shanghai-listed GRITEK subsidiary at terms favorable to the founder's complex over RS Tec minorities, or (3) a sharp expansion of the Rasa Industries stake without a clear strategic rationale. None of these have happened. All three are governance configurations the board structure as currently sized would struggle to challenge.
The one thing to watch. GRITEK is publicly listed in Shanghai and RS Tec just raised its stake via the January 2025 capital injection. How RS Tec's minority shareholders are treated as that subsidiary monetizes — versus how the Chinese strategic and Ho-controlled vehicles get treated — will be the next genuine test of whether this is a B that deserves to move higher, or a B that should have always been a C.